派瑞松治疗念珠菌性包皮龟头炎临床观察

采用派瑞松治疗念珠菌性包皮龟头炎,并与霉克进行对照。结果经1周的治疗,派瑞松组（30例）痊愈26例,显效3例,总显效率96．7％,起效时间为1．83天;霉克组（30例）痊愈19例,显效6例,总显效率83．3％,起效时间为2．5天。两组均未见不良反应。     

派瑞松霜治疗念珠菌性包皮龟头炎疗效观察

我科于 2 0 0 0年 6～ 9月应用派瑞松霜(西安杨森制药有限公司生产 )治疗念珠菌性包皮龟头炎 33例 ,取得较好疗效 ,现报告如下。临床资料　 33例均为我科门诊男性患者 ,年龄 19～ 5 1岁 ,平均 30岁 ,病程 2天～3个月 ,平均 2 6 .2天。所有患者均有不同程度包皮内板、龟头及冠状     

洁悠神长效抗菌材料治疗包皮龟头炎的临床观察

目的探寻一种创新的"皮肤物理抗菌膜"专利技术治疗包皮龟头炎的疗效。方法随机选取包皮龟头炎患者220例,治疗组120例,清洗后外用洁悠神喷洒于龟头、包皮,每日早晚各一次,该组同时取洁悠神喷洒内裤,1次/d,共1周。对照组100例,清洗后外用派瑞松霜,每日早晚各一次,共1周。停药后判定疗效。结果经过临床观察,两种治疗方法的痊愈率、显效率、好转率、无效率、总有效率无显著性差异(P0.05);用药7天真菌镜检阳性例数两组无显著性差异(P0.05)。结论洁悠神治疗由感染引起的包皮龟头炎与抗菌药物有同样疗效,但可避免抗菌药物引起的耐药性。     

派瑞松霜治疗皮炎湿疹的疗效观察

目的观察派瑞松霜治疗皮炎湿疹的疗效、耐受性及不良反应。方法60例患者来自门诊和住院病人,男55例,女5例。年龄14～87岁,平均71.1±15.1岁;病程2天～20年,平均9.5±25.1月。每日2次外用派瑞松霜涂于患处,每周随访1次,共3周。结果治愈33例(55.0％),显效16例(26.7％),好转4例(6.6％),无效7例(11.7％)。总有效率为81.7％,未发现不良反应。结论派瑞松霜是治疗皮炎湿疹类皮肤病的安全、有效药物。     

派瑞松霜治疗包皮龟头炎30例

我们于2000年5月-2000年10月应用派瑞松霜治疗包皮龟头炎30例，取得较好疗效，现报告如下。     

氟康唑治疗念珠菌性包皮龟头炎40例疗效观察

目的　观察氟康唑治疗念珠菌性包皮龟头炎临床疗效。方法　有条件选择 40例具有典型念珠菌性包皮龟头炎临床表现及念珠菌镜检阳性患者。给予氟康唑胶囊 (三维康 ) 15 0mg顿服。 1周后复查。 结果　 40例患者中痊愈 3 2例 ,占 80 % ;显效 6例 ,占 15 % ;有效 1例 ,占 5 % ;无效 0例 ,总有效率 95 %。结论　氟康唑治疗念珠菌性包皮龟头炎具有快速、服用简便、疗效确切的特点。     

派瑞松霜治疗异位性皮炎疗效观察

采用自身双侧对比法治疗 37例异位性皮炎。结果派瑞松霜痊愈 11例 (29.7％ ),显效 21例 (56.8％ ),好转 2例 (5.4％ ),无效 3例 (8.1％ ),对照组皮康霜痊愈 7例 (18.9％ ),显效 9例 (24.3％ ),好转 8例 (21.6％ ),无效 13例 (35.1％ )。派瑞松霜的疗效明显优于皮康霜 (χ 2=15.18,P< 0.01)。     

派瑞松霜治疗念珠菌性包皮龟头炎疗效观察

目的　观察派瑞松霜对念珠菌性包皮龟头炎 (CBP)的疗效。方法　 64例患者随机分为两组分别外涂派瑞松霜与 1%克霉唑霜 ,根据临床症状、体征及真菌镜检判定疗效。结果　两组总有效率比较差异有显著性 (P <0 .0 5 )。结论　派瑞松霜对CBP疗效好。     

派瑞松霜与盐酸特比萘芬乳膏治疗面部脂溢性皮炎的疗效对比

目的 比较派瑞松霜与盐酸特比萘芬乳膏(兰美抒霜)外用治疗面部脂溢性皮炎的疗效。方法 将面部脂溢性皮炎患者随机分为2组：治疗组45例，外用派瑞松霜，对照组42例，外用兰美抒霜，两组均为每日1次，疗程2周。结果 治疗组的痊愈率为68．89％，总有效率为95．56％；对照组的痊愈率为47．62％，总有效率为76．19％。经x^2检验，两组间差异有显著性，派瑞松霜的疗效优于兰美抒霜，未发现派瑞松霜有不良反应。结论 派瑞松霜治疗面部脂溢性皮炎更有效，更安全。     

派瑞松霜治疗浅部真菌病56例疗效观察

56例浅部真菌病，均经真菌学检查确诊，经派瑞松霜治疗3周后40例痊愈，13例显效，总有效率94.64%，疗后3周真菌清除率91.07%，未见不良反应。     

Fibroblasts induce the assembly of the macromolecules of the basement membrane

The mechanism regulating the deposition of basement membrane components (BMCs) in a polymeric structure at the junction with the connective tissues is not yet understood. Cultures and cocultures of epithelial BMC-producing cells (L2 or PER cells) and fibroblasts were prepared in several experimental conditions and the organization of BMCs was studied by immunofluorescence. The pattern of BMCs in pure cultures of L2 or pulmonary epithelial rat (PER) cells consisted of intra- and extracellular granular deposits. At very high density, the cell contours were also underlined by a disrupted network of BMC deposits. A different fibrillar plexus--containing laminin, collagen type IV, and heparan-sulfate proteoglycan resistant to deoxycholate treatment and distant from the cell membrane--was observed in cocultures of L2 or PER cells with fibroblasts. Fibrils of fibronectin and/or collagen type I were most often dissociated from this plexus of BMCs. Similar results were obtained by adding a conditioned medium of L2 or PER cells to confluent fibroblasts, even when the cells were killed. Pure laminin also bound to the fibroblast layer. A coated film of fibronectin or polymeric collagen type I was unable to bind BMC provided by a conditioned medium. It is suggested that molecule(s) synthesized by fibroblasts and deposited in the pericellular matrix are involved in the assembly of BMCs.